Aurobindo Pharma

Aurobindo Pharma enters US inhalation market with generic Advair launch

The launch marks Aurobindo Pharma's entry into the US inhalation market and expands its complex generics portfolio beyond conventional oral solid formulations

USFDA issues warning letter to Aurobindo Pharma's Telangana facility

Aurobindo Pharma on Friday said the US health regulator has issued a warning letter to a formulation manufacturing facility of its arm, Eugia Pharma Specialities Ltd, in Telangana. In May this year the company had stated that the US Food and Drug Administration (USFDA) inspected Unit-I, a formulation manufacturing facility of Eugia Pharma Specialities Ltd located at Telangana from February 16 to February 27, 2026. The inspection had concluded with four observations and the USFDA had determined the facility as 'official action indicated' (OAI). "Subsequent to OAI, the unit has received a warning letter," Aurobindo Pharma said in a regulatory filing. There is no impact on the existing supplies to the US markets, it added. The company further said the Unit I of Eugia Pharma Specialities Ltd, is contributing to about 2 per cent to company's overall group revenue. Aurobindo Pharma said it remains committed to working closely with the US FDA and continues to enhance its compliance on a

Q1 results today: Aurobindo Pharma, Biocon, PB Fintech, 130 more on Aug 5

Q1FY27 company results: Firms including JK Lakshmi Cement, Power Grid Corporation of India, Berger Paints, and Bikaji Foods are also to release their April-June earnings today

Aurobindo Pharma nears all-time high, up 30% in 4 months; more upside left?

Aurobindo Pharma stock hit a 52-week high at ₹1,585, and quoted close to its record high of ₹1,592 hit in September 2024. HDFC Securities maintains 'Add' rating on the stock.

Stocks to buy: Aurobindo Pharma, Delhivery, Ather Energy, says Ajit Mishra

Market outlook by Ajit Mishra: The analyst from Religare Broking expects Nifty to consolidate in the near-term; among stocks he recommends Delhivery, Ather Energy and Aurobindo Pharma.

Aurobindo Pharma gets US FTC nod for $250 million acquisition of Lannett

Aurobindo Pharma on Monday said its arm Aurobindo Pharma USA, Inc has received approval from the US Federal Trade Commission (FTC) for its USD 250 million acquisition of Lannett Company LLC. The transaction, valued at USD 250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of this month, Aurobindo Pharma said in a regulatory filing. Lannett, a Pennsylvania-based generic pharmaceutical company, specialises in the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances, the filing said. The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a US-based manufacturing facility to its network, it added. "This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our US-based manufacturing capabilities, and enhances our position i

Aurobindo Pharma stock jumps 2% after US FTC approves Lannett acquisition

Aurobindo Pharma received necessary approval from the US Federal Trade Commission (FTC) for the acquisition of the Lannett business.

Stocks to Watch, June 5: Rate sensitives, ICICI Bank, Tata Steel, Groww

Stocks to watch, June 5: Banks, auto, realty, consumer durables, Groww, Tata Steel among others to remain in focus today

Aurobindo Pharma share price plunges 7% as margins weigh on Q4 results

Aurobindo Pharma Q4 results 2026: Aurobindo Pharma has reported a 2 per cent rise in consolidated profit after tax to ₹920.84 crore in the fourth quarter ended March 31.

Stocks to watch today: ITC, Maruti Suzuki, Nykaa, LIC, LG Electronics

Stocks to Watch today, May 22, 2026: Nykaa, LIC, ITC, Honasa Consumer, and Maruti Suzuki are some of the key stocks to watch today

Nandish Shah of HDFC Sec suggests Bear Spread on Nifty; key levels here

Nandish Shah of HDFC Securities has shared a Bear Spread strategy on Nifty, and a Bull Spread strategy on Aurobindo Pharma.

Q4 results: ITC, Nykaa, LIC, MTNL, Aurobindo Pharma, and 181 more on May 21

Q4FY26 company results: Firms including Max Healthcare, Gail (India), Prestige Estates, Sun TV, Bikaji Foods International, Quick Heal and Icra are also to release their January-March earnings today

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Ex-date alert! Aurobindo Pharma, 3 others to remain in spotlight next week

Notably, Indian equity markets will remain closed on Tuesday, April 14, on account of Dr Baba Saheb Ambedkar Jayanti.

Stocks to Watch today: Rate sensitives, Infosys, Aurobindo Pharma, GAIL

Stocks to Watch today, April 8, 2026: Banks, Real estate, automobiles, Infosys, Aurobindo Pharma are some of the key stocks to watch today

Stocks to Watch today: Godrej Consumer, Aurobindo Pharma, IRFC, PC Jeweller

Stocks to Watch today, April 7, 2025: Godrej Consumer, Aurobindo Pharma, IRFC, ACME Solar Holdings, PC Jeweller, and Titagarh Rail are some of the key stocks to watch today

Aurobindo Pharma sets April 12 as record date for ₹800 crore buyback

Company to repurchase up to 54.24 lakh shares at Rs 1,475 apiece through tender offer route, with promoters also eligible to participate in the buyback

Aurobindo up 4%; stock hits 52-week high, outperforms in 2026; here's why

Aurobindo Pharma to evaluate and consider a proposal for the buyback company's fully paid-up equity shares in its board meet on April 6.

Granules, Aurobindo Pharma among top stocks to buy today; check targets

Kunal Kamble, senior technical research analyst at Bonanza, has recommended buying shares of Aurobindo Pharma, Granules India, and Wheels India today

Aurobindo gains 3%, stock hits 52-week high; JM Financial sees more upside

In the past one month, Aurobindo has outperformed the market by surging 9 per cent, as compared to 8.5 per cent decline in the BSE Sensex.